
Valneva announces extension of existing loan agreement
An add-on loan provides Valneva SE with immediate access to $50m, with an additional $50m available in Q4/2023. According to the vaccine maker, the...

German company aims for the first EU approval for cell-cultured meat
The Cultivated B (Heidelberg, Germany) is the first company in the world to pre-register a partially cell-based meat product with the European Food...

French Carthera closes €37.5m Series B financing round
A prominent (undisclosed) investor led the round alongside the European Innovation Council Fund (EICF) and existing investors including Panakès...

Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences (Paris, France) is using its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies....

Oxford Biomedica expands agreement with Cabaletta Bio
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients...

Mogrify Ltd extends Series A financing to $46m
The additional commitment of US$10m that results in US$46m raised was made by the new lead investors Astellas Venture Management and Parkwalk...

Bavarian Nordic A/S bags US$120m for smallpox vaccine
Under a deal with the US agency BARDA, Bavarian Nordic A/S (Copenhagen) will cash in US$96m in 2023 ffor the manufacturing of a n new buk product of...